Coltac Therapeutics
Preclinical Pharmaceutical Developing Bacteria-based Synthetic Positive Selection Screening System
Health Tech & Life Sciences
Private
Company Overview
Snapshot
Founded in January 2022, Coltac Therapeutics operates with 1–10 employees. The company has raised $5 million across two funding rounds.
Business overview
Coltac Therapeutics is a preclinical pharmaceutical company focused on drug discovery within the Health Tech & Life Sciences sector. The company develops and researches solutions for identifying next-generation molecular glues by leveraging its proprietary bacteria-based, synthetic positive selection screening system. Its core technology aims to advance biopharmaceutical and biotechnology applications, particularly in oncology and protein-related drug discovery, serving the healthcare and life sciences markets.
Log in to access full profile ›Company Intelligence Q&A
- What is Coltac Therapeutics' primary focus?
- Coltac Therapeutics specializes in preclinical pharmaceutical development, focusing on drug discovery for the next generation of molecular glues using a bacteria-based, synthetic positive selection screening system.
- When was Coltac Therapeutics founded?
- Coltac Therapeutics was founded in January 2022.
- What is the total capital raised by Coltac Therapeutics?
- Coltac Therapeutics has raised a total of $5 million across two funding rounds.
- What markets does Coltac Therapeutics serve?
- Coltac Therapeutics serves the healthcare and life sciences markets, with a focus on biotechnology and pharmaceuticals.